Biologics in the treatment of severe asthma in children and adults-updates 2024-2025.

The development of targeted mAbs has transformed the treatment of moderate-to-severe asthma. The main clinical trial outcomes have focused on exacerbation reduction and lung function improvement. In the past few years, there have been many high-quality studies examining pathophysiologic effects of the biologic therapies, giving insight into their downstream impacts. Clinical remission is a growing area of interest, and many studies highlight the utility as well as the limitations of commonly available biomarkers to predict treatment response. This review synthesizes the results of recent clinical trials and related topics focusing on relevant updates to the literature since 2024, highlighting new indications for use, predictors of response, safety data, real-world comparative effectiveness, remission, and mechanistic advances.